Feedback / Questions
CC-90002 - Inhibrx, BMS
CC-90002: Regulatory approval for NHL by 2022
(Celgene)
-
Dec 4, 2018 -
ASH 2018
Regulatory
•
Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
https://s22.q4cdn.com/728481125/files/doc_presentations/2018/12/ASH-2018-IR-Event_FINAL_deanimated_website-version.pdf
Dec 4, 2018
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious